Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Spanish real-life practice confirms zanubrutinib as a safe and effective option in relapsed or refractory marginal zone lymphoma: Results of a cohort of 118 patients on behalf of GELTAMO.

View Full Paper
Ask AI
Bookmark
Share

Authors

APAna Muntanola PratBreast Cancer Research FoundationJMJavier MarcoHospital General Universitario Morales MeseguerSRSergio RamosHospital Universitario Fundación Jiménez Díaz

Discussion

Loading...

Member takes

Implication

Retrospective cohort found zanubrutinib treatment led to 76% overall response rate in 118 patients with relapsed MZL, highlighting its clinical utility.

Key Points

  • Evaluate efficacy and safety of zanubrutinib in relapsed or refractory marginal zone lymphoma in clinical practice across Spain.
  • Retrospective cohort study involving 118 patients with R/R MZL at 39 centers
  • Patients received zanubrutinib after at least one anti-CD20-based regimen
  • Baseline characteristics, treatment responses, and adverse events were analyzed
  • Overall response rate was 76.0% with a complete response rate of 22.2%
  • One-year progression-free survival was 79.4% with better outcomes for patients with fewer prior treatments
  • Adverse events occurred in 34.1% of patients, with the most common being bleeding and infections

Cite This Study

Prat et al. (2025) studied this question.

synapsesocial.com/papers/69362f5a4fa91c937236db59https://doi.org/10.1182/blood-2025-5350
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Real-world effectiveness and safety of Zanubrutinib in Spanish patients with relapsed/refractory marginal zone lymphoma.2026
  2. 2Bruton's tyrosine kinase inhibitor zanubrutinib-based regimens in relapsed/refractory primary diffuse large B-cell lymphoma of central nervous system.2024
  3. 3Efficacy and safety of zanubrutinib combined with anti-CD20 monoclonal antibody-based regimens as first-line therapy in high-risk follicular lymphoma and marginal zone lymphoma: A single-arm retrospective study2025
  4. 4Efficacy and safety of zanubrutinib-containing regimens in patients with newly diagnosed Mantle Cell Lymphoma: Interim results from a Phase II investigator-initiated study2025
  5. 5Zanubrutinib plus rituximab as front-line treatment for mucosa-associated lymphoid tissue (MALT) lymphoma: A single-arm, phase II study (ZAMA).2026